COEP - NASDAQ
Coeptis Therapeutics, Inc.
$16.40
+0.0000%Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
At a Glance
Live SnapshotCoeptis Therapeutics, Inc. Management Team
Mr. Brian Cogley M.B.A.
Chief Financial Officer
Compensation
$200,000
Ms. Christine Elise Sheehy
Co-Founder and Vice President of Compliance & Corporate Secretary
Compensation
$83,769
Mr. David Mehalick
Co-Founder, Chairman of the Board, Chief Executive Officer & President
Compensation
$360,000
Mr. Daniel Alexander Yerace
Co-Founder, Vice President of Operations & Director
Compensation
$360,000
Dr. Colleen Delaney M.D., M.Sc.
Consultant
Compensation
$360,000
Coeptis Therapeutics, Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for COEP.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
COEP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | November 14, 2024 | December 18, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | November 17, 2023 | December 20, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 11, 2022 | November 02, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | April 05, 2022 | April 26, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | November 19, 2021 | December 16, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.